Switch theme
Sign up to access all valuation multiples
Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the common and costly chronic medical conditions globally. The company's product is KidneyIntelX which is being designed to make improvements in kidney disease diagnosis and prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.
2018
93
LTM Revenue $1.7M
Last FY EBITDA -$38.3M
$34.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Renalytix has a last 12-month revenue (LTM) of $1.7M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Renalytix achieved revenue of $3.1M and an EBITDA of -$38.3M.
Renalytix expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Renalytix valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.7M | XXX | $3.1M | XXX | XXX | XXX |
| Gross Profit | $1.7M | XXX | $0.2M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 7% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$38.3M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -1246% | XXX | XXX | XXX |
| EBIT | n/a | XXX | -$38.8M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | -1262% | XXX | XXX | XXX |
| Net Profit | -$25.2M | XXX | -$44.9M | XXX | XXX | XXX |
| Net Margin | -1462% | XXX | -1462% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $5.1M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Renalytix's stock price is GBP 0 (or $0).
Renalytix has current market cap of GBP 26.5M (or $35.6M), and EV of GBP 25.4M (or $34.2M).
See Renalytix trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $34.2M | $35.6M | XXX | XXX | XXX | XXX | $-0.16 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Renalytix has market cap of $35.6M and EV of $34.2M.
Renalytix's trades at 8.9x EV/Revenue multiple, and -0.7x EV/EBITDA.
Equity research analysts estimate Renalytix's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Renalytix has a P/E ratio of -1.1x.
See valuation multiples for Renalytix and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $35.6M | XXX | $35.6M | XXX | XXX | XXX |
| EV (current) | $34.2M | XXX | $34.2M | XXX | XXX | XXX |
| EV/Revenue | 14.8x | XXX | 8.9x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -0.7x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -0.7x | XXX | XXX | XXX |
| EV/Gross Profit | 14.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.1x | XXX | -0.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialRenalytix's revenue per employee in the last FY averaged $33K, while opex per employee averaged $0.4M for the same period.
Renalytix's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Renalytix's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Renalytix and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $33K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 406% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 1269% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Renalytix acquired XXX companies to date.
Last acquisition by Renalytix was XXXXXXXX, XXXXX XXXXX XXXXXX . Renalytix acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Renalytix founded? | Renalytix was founded in 2018. |
| Where is Renalytix headquartered? | Renalytix is headquartered in United Kingdom of Great Britain and Northern Ireland. |
| How many employees does Renalytix have? | As of today, Renalytix has 93 employees. |
| Who is the CEO of Renalytix? | Renalytix's CEO is Mr. James Renwick McCullough. |
| Is Renalytix publicy listed? | Yes, Renalytix is a public company listed on LON. |
| What is the stock symbol of Renalytix? | Renalytix trades under RENX ticker. |
| When did Renalytix go public? | Renalytix went public in 2018. |
| Who are competitors of Renalytix? | Similar companies to Renalytix include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Renalytix? | Renalytix's current market cap is $35.6M |
| What is the current revenue of Renalytix? | Renalytix's last 12 months revenue is $1.7M. |
| What is the current EV/Revenue multiple of Renalytix? | Current revenue multiple of Renalytix is 14.8x. |
| Is Renalytix profitable? | Yes, Renalytix is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
